… ment during and after coronary artery bypass grafting (CABG… reaches 100% of patients
undergoing thoracotomy.” The primary … ischemia in patients with coronary artery disease. Anesth …

… to statin therapy in patients undergoing CABG. To ensure … of statin treatment (4 days only)
as well as including patients at … that 5.6 million people with coronary artery disease were not …

… An additional two treatments were performed in this study … fibrinogen which are both potent
angiogenic factors. Over the … , providing a superior graft for patients undergoing CABG. The …

… important factors that have consistently emerged as the most potent … patients undergoing
isolated CABG at Tehran Heart Center from January 2002 to January 2007. In this study, CAD …

… obtained from patients undergo‐ing CABG surgery are … therapy in male patients with coronary
artery disease raised … most potent and versatile vasodilator with effective graft protection of …

… ; CABG, coronary artery bypass graft. This traditional viewpoint has undergone radical … by
attenuating the platelet release of potent prothrombotic and proinflammatory products and the …

… Compared with the CABG group, patients who underwent PCI … of PCI with DES and CABG
for patients with CAD and LV systolic … PCI with new-generation DES, more potent antiplatelet …

… on the basis of "diffuse coronary artery disease", since, in our … and has been shown to be a
potent inotropic agent following … -up of patients undergoing saphenous vein bypass surgery. …

… of advanced multivessel coronary artery disease (CAD) is … of diabetes mellitus among patients
who undergo CABG, more of … as adenosine diphosphate (a potent chemo-attractant and a …

… Coronary Artery Bypass Grafting (CABG) is the most common … considered Class 1 indications
for surgery in stable CAD [1]: … factors influence the decision to use a particular conduit? …